Results 51 to 60 of about 12,515 (211)
Advanced Science, Volume 12, Issue 4, January 27, 2025.Tumors develop resistance to therapeutic agents, unfortunately, efforts to overcome resistance have achieved limited success. m6A RNA modification dysregulation is an emerging mechanism for cancer therapy resistance. This review comprehensively discusses recent studies regarding the contributions of m6A modification and its regulators to cancer therapy
Mohammad Burhan Uddin +2 more
wiley +1 more source
Malignancy Spectrum, Volume 1, Issue 4, Page 312-322, December 2024.Melanoma patients initiating treatements with dabrafenib + trametinib (Dab + Tram, n = 74; 67 non‐adjuvant and seven adjuvant) or encorafenib + binimetinib (Enco + Bini, n = 16) were identified in the Japanese MDV database. Median treatment duration was 11.8 months with Dab + Tram and 8.1 months with Enco + Bini.
Kenjiro Namikawa +3 more
wiley +1 more source
Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
Acta Medica Alanya, 2020 Aim: Imatinib mesylate is a tyrosine kinase inhibitor and is approved as a standard first-line therapy of chronic myeloid leukemia. Oxidative stress, as well as intracellular calcium overload and mitochondrial dysfunction, play an important role in ...
İshak Suat Övey, Can Ramazan Öncel
doaj
Association Free Energies of Metal Cations with Mesylate and Acetate in Brine Calculated via Molecular Dynamics Simulation [PDF]
arXiv, 2018 Here we report results from fully-atomistic molecular dynamics simulations and present the calculated binding free energies of the associations between metal cations and anionic functional groups under brine condition. Specifically the ion pair formations of Na+ and Ca2+ metal cations with sulfonate and carboxylate functional groups were considered. In
arxiv
XML Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
Iranian Journal of Blood and Cancer, 2016 Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML).
Abolghasem Allahyari +3 more
doaj
Imatinib and hypophosphatemia: Case report and review of literature
Journal of Oncological Sciences, 2017 Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated.
Erdem Şen, İrem Öner, Özlem Ata
doaj +1 more source
British Journal of Haematology, Volume 205, Issue 6, Page 2136-2138, December 2024.Hypereosinophilic syndromes (HES) comprise different clonal, reactive, or idiopathic disorders characterized by elevated eosinophil levels and subsequent organ damage. Kim et al. in a multicentre, single‐arm, prospective phase II study, treated 32 patients with PDGFRA/B‐negative HES with imatinib at the dose of 100–400 mg daily.
Giuseppe G. Loscocco, Grzegorz Helbig
wiley +1 more source
Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia [PDF]
Oncotarget, Impact journals, 2018, 2019 Background: Chronic myeloid leukemia (CML) results from hematopoietic stem cell transformation by the bcr-abl chimeric oncogene, encoding a 210 kDa protein with constitutive tyrosine kinase activity. In spite of the efficiency of tyrosine kinase inhibitors (TKI; Imatinib), other strategies are explored to eliminate CML leukemia stem cells, such as ...
arxiv
Clinical and Translational Science, Volume 17, Issue 11, November 2024.Abstract Molecular targeted tyrosine kinase inhibitors (TKIs) have produced unprecedented treatment response in cancer therapy for patients harboring specific oncogenic mutations. While the TKIs are mostly well tolerated, they were reported to increase serum levels of creatine kinase (CK) and cause muscle metabolism‐related toxicity. CK is an essential
Hang Zhang, Kenneth K. W. To
wiley +1 more source
Molecular Therapy: Oncolytics, 2021 Resistance to the BCR-ABL inhibitor imatinib mesylate poses a major problem for the treatment of chronic myeloid leukemia. Imatinib resistance often results from a secondary mutation in BCR-ABL that interferes with drug binding.
Yanjun Liu +8 more
doaj